-
公开(公告)号:US20230026049A1
公开(公告)日:2023-01-26
申请号:US17661207
申请日:2022-04-28
Inventor: Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC: C07K16/28 , C07K14/725 , C07K14/705 , C07K14/74 , C12N9/90 , C12N9/12 , C07K14/71 , A61K31/436 , A61K35/17
Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号:US20210139585A1
公开(公告)日:2021-05-13
申请号:US16877878
申请日:2020-05-19
Applicant: Novartis AG
Inventor: Brian Granda , Amy Rayo , Connie Hong , Dattananda Chelur , Haihui Lu , Regis Cebe , Sunyoung Jang
Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
-
3.
公开(公告)号:US10525083B2
公开(公告)日:2020-01-07
申请号:US15727402
申请日:2017-10-06
Inventor: Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号:US12037378B2
公开(公告)日:2024-07-16
申请号:US17612993
申请日:2020-05-19
Applicant: NOVARTIS AG
Inventor: Barbara Brannetti , Dattananda Chelur , Brian Granda , Connie Hong
IPC: C07K14/705
CPC classification number: C07K14/70528
Abstract: The present disclosure provides CD2 binding molecules that specifically bind to CD2, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD2 binding molecules, and pharmaceutical compositions comprising the CD2 binding molecules and the conjugates. The disclosure further provides methods of using the CD2 binding molecules to modulate CD2 signaling in order to treat a variety of immune (e.g., autoimmune), inflammatory and proliferative disorders. The disclosure yet further provides recombinant host cells engineered to express the CD2 binding molecules and methods of producing the CD2 binding molecules by culturing the host cells under conditions in which the CD2 binding molecules are expressed.
-
公开(公告)号:US20240083968A1
公开(公告)日:2024-03-14
申请号:US18304956
申请日:2023-04-21
Inventor: Andreas Loew , Brian Granda , Melissa Ramones
IPC: C07K14/725 , C07K16/28 , C07K16/30 , C07K19/00
CPC classification number: C07K14/7051 , C07K16/2803 , C07K16/30 , C07K19/00 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C07K2319/70
Abstract: The present invention features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the invention is based, in part, on the discovery that chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3 epsilon) having all or most of their extracellular domain fused to an antigen binding domain can activate the TCR in the presence of a cognate antigen. The invention is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the invention include an antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain.
-
公开(公告)号:US11578130B2
公开(公告)日:2023-02-14
申请号:US16210480
申请日:2018-12-05
Inventor: Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC: C07K16/28 , A61K31/436 , A61K35/17 , C07K14/705 , C07K14/71 , C07K14/725 , C07K14/74 , C12N9/12 , C12N9/90
Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
7.
公开(公告)号:US20200055948A1
公开(公告)日:2020-02-20
申请号:US16608519
申请日:2018-04-27
Inventor: Michael Daley , Brian Granda , Michael C. Milone , Selene Guadalupe Nunez Cruz
IPC: C07K16/28 , A61K35/17 , A61K39/395 , A61K31/55 , A61K31/381 , A61K31/4245 , A61K31/19 , A61K38/05 , A61K31/5513 , A61K31/417 , C07K16/40 , C12N15/113 , A61P35/00 , A61K45/06 , C07K14/725 , A61K38/17
Abstract: The invention relates to the treatment of diseases associated with expression of BCMA, in particular myelomas. The invention relates to combination therapies of a BCMA CAR-expressing cell and a gamma secretase inhibitor.
-
公开(公告)号:US10287354B2
公开(公告)日:2019-05-14
申请号:US15105074
申请日:2014-12-19
Inventor: Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC: C07K16/28 , A61K31/436 , A61K35/17 , C07K14/705 , C07K14/71 , C07K14/725 , C12N9/90 , C07K14/74
Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号:US12221481B2
公开(公告)日:2025-02-11
申请号:US16877878
申请日:2020-05-19
Applicant: Novartis AG
Inventor: Brian Granda , Amy Rayo , Connie Hong , Dattananda Chelur , Haihui Lu , Regis Cebe , Sunyoung Jang
Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
-
10.
公开(公告)号:USRE49847E1
公开(公告)日:2024-02-27
申请号:US17569389
申请日:2022-01-05
Inventor: Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC classification number: A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
-
-
-
-
-
-
-
-